+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Scleroderma Diagnostics & Therapeutics Market by Diagnostic Tests (Blood Tests, Imaging, Pulmonary Function Tests), Drug Type (Calcium Channel Blockers, Chelating Agents, Corticosteroids), Therapeutics, Indication - Forecast 2024-2030

  • PDF Icon

    Report

  • 186 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 5888912
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Scleroderma Diagnostics & Therapeutics Market size was estimated at USD 2.09 billion in 2023, USD 2.19 billion in 2024, and is expected to grow at a CAGR of 6.25% to reach USD 3.20 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Scleroderma Diagnostics & Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Scleroderma Diagnostics & Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Scleroderma Diagnostics & Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Antibodies Inc., AstraZeneca plc, Bayer AG, Bio-Rad Laboratories, Inc, Biogen Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Exagen Inc., F. Hoffmann-La Roche Ltd., Galapagos NV, Gilead Sciences, Inc., GlaxoSmithKline plc (GSK), Merck & Co., Inc., Myriad Genetics, Inc, Novartis AG, PerkinElmer Inc., Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi Genzyme, Takeda Pharmaceutical Company Limited, The Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., and Trinity Biotech plc.

Market Segmentation & Coverage

This research report categorizes the Scleroderma Diagnostics & Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Diagnostic Tests
    • Blood Tests
    • Imaging
      • CT Scans
      • MRI
      • X-rays
    • Pulmonary Function Tests
    • Skin Biopsies
  • Drug Type
    • Calcium Channel Blockers
    • Chelating Agents
    • Corticosteroids
    • Endothelin Receptor Agonists
    • Immunosuppressive Agents
    • PDE-5 Inhibitors
    • Prostacyclin Analogues
  • Therapeutics
    • Biologic Therapies
    • Gene Therapy
    • Pulmonary Fibrosis Treatments
    • Raynaud's Phenomenon Management
    • Stem Cell Transplantation
  • Indication
    • Localized
    • Systemic
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast of the Scleroderma Diagnostics & Therapeutics Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Scleroderma Diagnostics & Therapeutics Market?
  3. What are the technology trends and regulatory frameworks in the Scleroderma Diagnostics & Therapeutics Market?
  4. What is the market share of the leading vendors in the Scleroderma Diagnostics & Therapeutics Market?
  5. Which modes and strategic moves are suitable for entering the Scleroderma Diagnostics & Therapeutics Market?

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Purchase of this report includes 1 year online access with quarterly updates

Purchase of this report includes 1 year online access with quarterly updates

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Scleroderma Diagnostics & Therapeutics Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of scleroderma and the need for effective diagnostic techniques and therapies
5.1.1.2. Growing awareness about scleroderma condition and emphasis on early diagnosis
5.1.1.3. Rising number of clinical trials for the development of novel drugs and therapies
5.1.2. Restraints
5.1.2.1. High cost associated with scleroderma treatment
5.1.3. Opportunities
5.1.3.1. Advancements in diagnostic technologies, such as imaging techniques and biomarker identification
5.1.3.2. Ongoing research for identifying efficient treatment options for scleroderma
5.1.4. Challenges
5.1.4.1. Side effects associated with the drugs used in scleroderma treatment
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Scleroderma Diagnostics & Therapeutics Market, by Diagnostic Tests
6.1. Introduction
6.2. Blood Tests
6.3. Imaging
6.4.1. CT Scans
6.4.2. MRI
6.4.3. X-rays
6.4. Pulmonary Function Tests
6.5. Skin Biopsies
7. Scleroderma Diagnostics & Therapeutics Market, by Drug Type
7.1. Introduction
7.2. Calcium Channel Blockers
7.3. Chelating Agents
7.4. Corticosteroids
7.5. Endothelin Receptor Agonists
7.6. Immunosuppressive Agents
7.7. PDE-5 Inhibitors
7.8. Prostacyclin Analogues
8. Scleroderma Diagnostics & Therapeutics Market, by Therapeutics
8.1. Introduction
8.2. Biologic Therapies
8.3. Gene Therapy
8.4. Pulmonary Fibrosis Treatments
8.5. Raynaud's Phenomenon Management
8.6. Stem Cell Transplantation
9. Scleroderma Diagnostics & Therapeutics Market, by Indication
9.1. Introduction
9.2. Localized
9.3. Systemic
10. Americas Scleroderma Diagnostics & Therapeutics Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Scleroderma Diagnostics & Therapeutics Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Scleroderma Diagnostics & Therapeutics Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player
14. Competitive Portfolio
14.1. Key Company Profiles
14.1.1. AbbVie Inc.
14.1.2. Amgen Inc.
14.1.3. Antibodies Inc.
14.1.4. AstraZeneca plc
14.1.5. Bayer AG
14.1.6. Bio-Rad Laboratories, Inc
14.1.7. Biogen Inc.
14.1.8. Boehringer Ingelheim Pharmaceuticals, Inc.
14.1.9. Eli Lilly and Company
14.1.10. Exagen Inc.
14.1.11. F. Hoffmann-La Roche Ltd.
14.1.12. Galapagos NV
14.1.13. Gilead Sciences, Inc.
14.1.14. GlaxoSmithKline plc (GSK)
14.1.15. Merck & Co., Inc.
14.1.16. Myriad Genetics, Inc
14.1.17. Novartis AG
14.1.18. PerkinElmer Inc.
14.1.19. Pfizer Inc.
14.1.20. Regeneron Pharmaceuticals, Inc.
14.1.21. Sanofi Genzyme
14.1.22. Takeda Pharmaceutical Company Limited
14.1.23. The Bristol-Myers Squibb Company
14.1.24. Thermo Fisher Scientific Inc.
14.1.25. Trinity Biotech plc.
14.2. Key Product Portfolio
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing
List of Figures
FIGURE 1. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2023 VS 2030
FIGURE 3. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET DYNAMICS
FIGURE 7. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2023 VS 2030 (%)
FIGURE 8. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
FIGURE 10. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2023 VS 2030 (%)
FIGURE 12. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 14. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. AMERICAS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 18. UNITED STATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 24. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
List of Tables
TABLE 1. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 6. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 9. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CT SCANS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MRI, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY X-RAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PULMONARY FUNCTION TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SKIN BIOPSIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 15. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHELATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ENDOTHELIN RECEPTOR AGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSIVE AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PDE-5 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PROSTACYCLIN ANALOGUES, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 23. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOLOGIC THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PULMONARY FIBROSIS TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RAYNAUD'S PHENOMENON MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 29. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY LOCALIZED, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SYSTEMIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 37. ARGENTINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 38. ARGENTINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 39. ARGENTINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 40. ARGENTINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 41. ARGENTINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 42. BRAZIL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 43. BRAZIL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 44. BRAZIL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 45. BRAZIL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 46. BRAZIL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 47. CANADA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 48. CANADA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 49. CANADA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 50. CANADA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 51. CANADA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 52. MEXICO SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 53. MEXICO SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 54. MEXICO SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 55. MEXICO SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 56. MEXICO SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 63. ASIA-PACIFIC SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 64. ASIA-PACIFIC SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 65. ASIA-PACIFIC SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 66. ASIA-PACIFIC SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 67. ASIA-PACIFIC SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 68. ASIA-PACIFIC SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 69. AUSTRALIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 70. AUSTRALIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 71. AUSTRALIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 72. AUSTRALIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 73. AUSTRALIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 74. CHINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 75. CHINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 76. CHINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 77. CHINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 78. CHINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 79. INDIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 80. INDIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 81. INDIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 82. INDIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 83. INDIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 84. INDONESIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 85. INDONESIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 86. INDONESIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 87. INDONESIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 88. INDONESIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 89. JAPAN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 90. JAPAN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 91. JAPAN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 92. JAPAN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 93. JAPAN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 94. MALAYSIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 95. MALAYSIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 96. MALAYSIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 97. MALAYSIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 98. MALAYSIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 99. PHILIPPINES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 100. PHILIPPINES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 101. PHILIPPINES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 102. PHILIPPINES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 103. PHILIPPINES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 104. SINGAPORE SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 105. SINGAPORE SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 106. SINGAPORE SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 107. SINGAPORE SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 108. SINGAPORE SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 109. SOUTH KOREA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 110. SOUTH KOREA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 111. SOUTH KOREA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 112. SOUTH KOREA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 113. SOUTH KOREA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 114. TAIWAN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 115. TAIWAN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 116. TAIWAN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 117. TAIWAN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 118. TAIWAN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 119. THAILAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 120. THAILAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 121. THAILAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 122. THAILAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 123. THAILAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 124. VIETNAM SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 125. VIETNAM SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 126. VIETNAM SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 127. VIETNAM SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 128. VIETNAM SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 135. DENMARK SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 136. DENMARK SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 137. DENMARK SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 138. DENMARK SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 139. DENMARK SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 140. EGYPT SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 141. EGYPT SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 142. EGYPT SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 143. EGYPT SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 144. EGYPT SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 145. FINLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 146. FINLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 147. FINLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 148. FINLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 149. FINLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 150. FRANCE SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 151. FRANCE SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 152. FRANCE SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 153. FRANCE SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 154. FRANCE SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 155. GERMANY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 156. GERMANY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 157. GERMANY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 158. GERMANY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 159. GERMANY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 160. ISRAEL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 161. ISRAEL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 162. ISRAEL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 163. ISRAEL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 164. ISRAEL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 165. ITALY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 166. ITALY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 167. ITALY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 168. ITALY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 169. ITALY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 170. NETHERLANDS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 171. NETHERLANDS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 172. NETHERLANDS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 173. NETHERLANDS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 174. NETHERLANDS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 175. NIGERIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 176. NIGERIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 177. NIGERIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 178. NIGERIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 179. NIGERIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 180. NORWAY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 181. NORWAY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 182. NORWAY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 183. NORWAY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 184. NORWAY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 185. POLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 186. POLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 187. POLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 188. POLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 189. POLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 190. QATAR SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 191. QATAR SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 192. QATAR SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 193. QATAR SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 194. QATAR SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 195. RUSSIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 196. RUSSIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 197. RUSSIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 198. RUSSIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 199. RUSSIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 200. SAUDI ARABIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 201. SAUDI ARABIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 202. SAUDI ARABIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 203. SAUDI ARABIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 204. SAUDI ARABIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 206. SOUTH AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 207. SOUTH AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 208. SOUTH AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 209. SOUTH AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 210. SPAIN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 211. SPAIN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 212. SPAIN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 213. SPAIN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 214. SPAIN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 215. SWEDEN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 216. SWEDEN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 217. SWEDEN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 218. SWEDEN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 219. SWEDEN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 220. SWITZERLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 221. SWITZERLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 222. SWITZERLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 223. SWITZERLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 224. SWITZERLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 225. TURKEY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 226. TURKEY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 227. TURKEY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 228. TURKEY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 229. TURKEY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 231. UNITED ARAB EMIRATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 232. UNITED ARAB EMIRATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 233. UNITED ARAB EMIRATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 234. UNITED ARAB EMIRATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 236. UNITED KINGDOM SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 237. UNITED KINGDOM SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 238. UNITED KINGDOM SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 239. UNITED KINGDOM SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 240. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 241. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 242. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET LICENSE & PRICING

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AbbVie Inc.
  • Amgen Inc.
  • Antibodies Inc.
  • AstraZeneca plc
  • Bayer AG
  • Bio-Rad Laboratories, Inc
  • Biogen Inc.
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • Eli Lilly and Company
  • Exagen Inc.
  • F. Hoffmann-La Roche Ltd.
  • Galapagos NV
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc (GSK)
  • Merck & Co., Inc.
  • Myriad Genetics, Inc
  • Novartis AG
  • PerkinElmer Inc.
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi Genzyme
  • Takeda Pharmaceutical Company Limited
  • The Bristol-Myers Squibb Company
  • Thermo Fisher Scientific Inc.
  • Trinity Biotech plc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages186
PublishedMarch 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 2.19 Billion
Forecasted Market Value ( USD ) by 2030 $ 3.2 Billion
Compound Annual Growth Rate6.2%
Regions CoveredGlobal

Related Topics

Related Reports

Global Scleroderma Diagnostics and Therapeutics Market by Disease Type, by Drugs, by Diagnosis, by End-User, and By Region - Product Image

Global Scleroderma Diagnostics and Therapeutics Market by Disease Type, by Drugs, by Diagnosis, by End-User, and By Region

  • Report
  • 200 Pages
  • Global
From
Scleroderma Diagnostics and Therapeutics - Global Strategic Business Report - Product Image

Scleroderma Diagnostics and Therapeutics - Global Strategic Business Report

  • Report
  • 194 Pages
  • Global
From
Systemic Scleroderma - Pipeline Insight, 2024 - Product Image

Systemic Scleroderma - Pipeline Insight, 2024

  • Clinical Trials
  • 60 Pages
  • Global
From
Localized Scleroderma - Pipeline Insight, 2024 - Product Image

Localized Scleroderma - Pipeline Insight, 2024

  • Clinical Trials
  • 60 Pages
  • Global
From
Thyroid Function Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 - Product Image

Thyroid Function Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033

  • Report
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.